 |
|
 |
 |
|
||||||||||||||
|
Anti-Obesity Drug Acomplia May Alleviate Cholesterol Too July 13, 2007 Believing in the report of recent study carried out on rats, the anti-obesity drug rimonabant might help people in diminishing liver damage and improving levels of cholesterol. Marketed in Europe as Acomplia, rimonabant is still not approved for sale in the United States. During this study, obese male rats were daily medicated with acomplia for eight weeks by French researchers at Sanofi-Aventis, the pharmaceutical giant who invented this revolutionary anti-obesity drug. And in the conclusion, researchers noticed remarkable decrease in the rodents' liver amplification in addition to a drop in the fat level within the liver and markers representing liver damage. Besides, the notable decline was also found in an inflammation-related protein that is believed to cause insulin resistance in the liver. The researchers also found improved levels of cholesterol and triglyceride in obese rats post treatment. They imputed the development to enhanced wellbeing of the liver. According to the data proposed by American College of Gastroenterology,
two out of three obese adults also suffer from nonalcoholic fatty
liver disease, an accretion of fat in the liver. At worst, this
condition can even develop into liver inflammation, cirrhosis and
tissue scarring.
|
||||||||||||||
